Noxopharm has replied to the USPTO requirement to refine their...

  1. RBx
    643 Posts.
    lightbulb Created with Sketch. 1002
    Noxopharm has replied to the USPTO requirement to refine their patent application
    IMPROVEMENTS IN CANCER TREATMENT
    by defining Idronoxil as their 'elected species'.

    Any claims for other species that were withdrawn can be pursued in subsequent applications.

    Moving forward, as expected.  Harvett will no doubt take exception, but who cares?
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
9.5¢
Change
-0.003(3.06%)
Mkt cap ! $27.76M
Open High Low Value Volume
9.5¢ 9.5¢ 9.5¢ $570 6K

Buyers (Bids)

No. Vol. Price($)
2 77757 9.3¢
 

Sellers (Offers)

Price($) Vol. No.
9.8¢ 8403 1
View Market Depth
Last trade - 13.55pm 15/09/2025 (20 minute delay) ?
NOX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.